FOSUN HEALTH Logo

Leukemia Treatment

catalogue

Leukemia Treatment

Leukemia Treatment

Leukemia treatment is organised by type and by risk group, and the difference between the types is greater than in almost any other group of cancers. A patient with acute myeloid leukemia begins intensive inpatient chemotherapy within days of diagnosis; a patient with chronic myeloid leukemia begins a tablet that is taken every day and monitored by a blood test; a patient with early chronic lymphocytic leukemia may begin no treatment at all. The type, always stated in full, is what determines which of those applies.

How the type decides the route

The type and the risk group together settle four questions, and they are answered as a set rather than one after another:

  • How urgent the start is. Acute leukemias are treated within days, and one subtype within hours; chronic leukemias may be monitored for a period before any treatment is given.
  • Whether treatment is intensive and finite, or continuous. Acute leukemias are treated in phases that end; chronic myeloid leukemia is treated continuously with an oral drug, and can in some patients eventually be stopped after a deep and sustained response.
  • Whether a targeted drug is added. The fusion gene or mutation found at diagnosis determines whether a tyrosine kinase inhibitor, a FLT3 inhibitor, an IDH inhibitor or a BCL2 inhibitor belongs in the regimen.
  • Whether a transplant is planned. Adverse-risk disease in first remission and relapsed disease are the two main situations in which a transplant is considered, and it is discussed at the outset rather than at the moment it is needed.

Three things that do not decide the route are worth naming. Age, on its own, does not: it changes which regimen is safe and how doses are adjusted, but older patients are treated with curative intent using regimens designed for them. A high white cell count at presentation does not, although it requires its own management to prevent complications. And the fact that treatment is described as palliative in some settings does not mean the chronic leukemias are untreated — they are treated continuously and often for many years, which is a different situation from a palliative plan in an acute disease.

Acute myeloid leukemia

Treatment of acute myeloid leukemia is given in phases, and the first phase is the one that must not be delayed. The structure is as follows:

  • Induction — combination chemotherapy, usually an anthracycline with cytarabine given over about a week, with the aim of clearing the marrow of leukemic cells and allowing normal production to resume. It is given as an inpatient because the counts fall before they recover.
  • A bone marrow assessment after induction — to establish whether the disease has cleared, which determines what consolidation is given.
  • Consolidation — further chemotherapy, sometimes given at higher doses, whose purpose is to eliminate disease that is no longer detectable by ordinary examination.
  • Targeted agents matched to the genes — a FLT3 inhibitor added to first-line treatment and used in relapse; IDH inhibitors for the corresponding mutations; and an antibody-drug conjugate directed at CD33 in favourable-risk disease.
  • A regimen designed for older or less fit patients — a BCL2 inhibitor with a hypomethylating agent, which produces remissions without the intensity of standard induction.
  • A distinct regimen for acute promyelocytic leukemia — all-trans retinoic acid and arsenic trioxide, without conventional chemotherapy, with treatment starting before the molecular confirmation is complete.
  • A formulation for secondary or therapy-related disease — a liposomal combination designed for leukemia following another cancer or a preceding marrow disorder.

Acute lymphoblastic leukemia

Acute lymphoblastic leukemia is treated with a longer, more complex programme than acute myeloid leukemia, and it is the disease in which treatment lasts years rather than months:

  • A backbone of several drugs — vincristine, a corticosteroid, an anthracycline, asparaginase and others, given in phases: remission induction, consolidation, and then a prolonged maintenance period.
  • Treatment directed at the nervous system — given into the spinal fluid and in some regimens at high dose intravenously, because leukemic cells can persist there while the marrow is clear.
  • A tyrosine kinase inhibitor for the subtype carrying the fusion gene that gives rise to the Philadelphia chromosome, and for disease with a Philadelphia-like signature, which has transformed the outlook for those groups.
  • A bispecific antibody directed at CD19, used for disease that does not clear completely or that returns, and increasingly earlier in the pathway.
  • An antibody-drug conjugate directed at CD22 for relapsed or refractory B-cell disease, including as a step towards transplant.
  • CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia, particularly in children and young adults.
  • Maintenance treatment — continued oral chemotherapy for a period measured in years, which is what prevents late relapse and is therefore not optional.

Chronic myeloid leukemia

Chronic myeloid leukemia is the disease in which an oral drug changed what the diagnosis means. Treatment is continuous rather than finite, and it is monitored by measuring the fusion gene in the blood:

  • Tyrosine kinase inhibitors — four drugs are in routine use, and the choice among them depends on the phase of the disease, the side-effect profile that matters most to the patient, and any other medical conditions.
  • A defined response target — the level of the fusion gene in the blood at fixed intervals, measured on an internationally standardised scale, defines whether the drug is working.
  • Switching rather than stopping — if the response is not adequate, the usual step is to change to another drug of the same class rather than to add chemotherapy.
  • Treatment-free remission in selected patients — a small group who stay in a deep and sustained response for several years may be able to stop treatment under close monitoring, and can restart it if the level rises.
  • Transplant reserved for specific situations — disease that has progressed beyond the chronic phase, or that has not responded to several drugs, including those with the mutation that makes most inhibitors ineffective.

Chronic lymphocytic leukemia

Chronic lymphocytic leukemia is the most common leukemia in adults in Western countries and the one most often found by accident. Its management begins with deciding not to treat:

  • Monitoring at fixed intervals — the recommended approach for early-stage disease, because treating it before there is a reason has not been shown to lengthen life.
  • Targeted drugs rather than chemotherapy as first-line treatment — a Bruton tyrosine kinase inhibitor given continuously, or a BCL2 inhibitor with an antibody given for a fixed duration, both of which have displaced chemotherapy for most patients.
  • Chemoimmunotherapy retained in a narrow group — fit patients with a favourable molecular profile, in whom a fixed-duration combination remains an option.
  • Test-directed choice — the IGHV mutation status and TP53 status influence whether chemotherapy has any role, which is why both are tested before first-line treatment.
  • Recognising transformation — sudden enlargement of nodes, new systemic symptoms or a rapid change in blood counts require a biopsy, because transformation to an aggressive lymphoma is treated as a separate disease.
  • Cell therapy and transplant for specific situations — used in transformation or in disease resistant to targeted drugs, in selected patients.

Stem cell transplant and CAR T-cell therapy

Two treatments are used when the disease is high-risk at diagnosis or has returned, and both are planned rather than improvised:

  • Allogeneic stem cell transplant — stem cells from a matched sibling, an unrelated donor or a half-matched family member. It is the definitive treatment for high-risk acute leukemia in first remission, and for relapsed disease that has been brought back into remission. The immune reaction from the donor's cells contributes to controlling the leukemia, which is why it works where chemotherapy alone has not.
  • Donor search in parallel with treatment — because identifying a donor takes weeks, and only a minority of patients have a matched sibling, the search is started as soon as a transplant is a possibility rather than after the decision is made.
  • CAR T-cell therapy — T cells are collected, engineered to recognise CD19 and returned; used for relapsed or refractory B-cell acute lymphoblastic leukemia, and for some other B-cell diseases.
  • Bispecific antibodies as an alternative route to remission — used to clear disease before a transplant when cell therapy is not suitable, unavailable or has already been given.

Supportive care during treatment

In leukemia, supportive care is not an adjunct to treatment — it is what allows the treatment to be completed, and it is often what patients remember most:

  • Anti-infective prophylaxis — antibacterial, antifungal and antiviral medication given in advance, not only when an infection appears.
  • Transfusion support — red cells and platelets given according to defined thresholds rather than to symptoms alone.
  • Tumour lysis prevention — fluids and a drug that lowers uric acid, started before treatment when the disease burden is high, because the first days carry the greatest risk.
  • Management of a very high white cell count — including measures to reduce it before chemotherapy begins, when it is high enough to affect the circulation through small vessels.
  • Growth factor support — used in some regimens to shorten the period of low white cells.
  • Nutrition and mouth care — mucositis and loss of appetite are common, and both affect how the next phase is tolerated.

The practical implication is that supportive care should be written into the plan rather than added when a problem appears. It also has a bearing on where treatment can be delivered: a regimen that requires intensive support for several weeks belongs in a centre that provides it, and the arrangements for prophylaxis, transfusion and complication management are part of what a patient should ask about before committing to a plan.

How the treatment plan is decided

The decisions in leukemia are interdependent, which is why they are settled together. A plan should answer these questions:

  • What is the exact subtype, and what is the risk group? Named from the marrow, flow cytometry and molecular results, and reviewed where the diagnosis is uncommon.
  • Which regimen, and how many phases? Including any targeted drug and the specific mutation it matches.
  • When will the response be measured, and by which test? The dates of marrow assessment and measurable residual disease testing, and the thresholds that would change the plan.
  • Is a transplant part of the plan, and if so when? Stated in first remission where the risk group indicates it, with donor search begun alongside treatment.
  • What supportive measures are needed? Prophylaxis, transfusion, tumour lysis prevention, and fertility preservation before the first dose.
  • What happens if the disease does not respond or returns? The salvage strategy and whether cell therapy would be appropriate.

Frequently Asked Questions

Will I need a bone marrow transplant?

Not necessarily, and the answer depends on the subtype and the risk group rather than on the diagnosis alone. In acute myeloid leukemia, a favourable risk group often means chemotherapy alone is expected to suffice, while an adverse risk group usually means a transplant is discussed in first remission. In acute lymphoblastic leukemia, the decision depends on the molecular findings and how deeply the disease responds. In chronic myeloid leukemia, a transplant is reserved for disease that has progressed beyond the chronic phase or has not responded to several drugs. The question is worth asking at the outset, because if a transplant is a possibility the donor search should begin alongside treatment.

How long does leukemia treatment last?

It varies enormously by type. Acute myeloid leukemia is treated in phases over several months, with the first phase usually involving a hospital stay of four to six weeks. Acute lymphoblastic leukemia involves a programme measured in years, including a maintenance period that is essential rather than optional. Chronic myeloid leukemia is treated continuously with an oral drug, and in a small group of patients who achieve a deep and sustained response treatment may eventually be stopped under monitoring. Chronic lymphocytic leukemia may need no treatment at all for years, then a fixed course or a continuous tablet.

Can I have a transplant or cell therapy in China?

Both are available in our network. Allogeneic transplant is offered using matched siblings, unrelated donors through the registry, and half-matched family donors, which means patients without a matched sibling can still be treated — a situation that applies to the majority. CAR T-cell therapy is available for relapsed or refractory B-cell acute lymphoblastic leukemia. What matters for planning is timing: identifying a donor or arranging cell therapy takes weeks, so both should be raised early rather than when the situation becomes urgent. Ask about the centre's experience with the specific approach and about follow-up arrangements if you live abroad.

What if treatment does not work?

There is usually a defined next step, and it depends on the type and on what has already been given. Disease that does not clear after induction in acute myeloid leukemia is treated with a different regimen, often containing a targeted drug matched to the mutation. Disease that returns after remission is treated with salvage chemotherapy followed by a transplant if a remission can be achieved again. In B-cell acute lymphoblastic leukemia, a bispecific antibody, an antibody-drug conjugate or CAR T-cell therapy can be used to clear the disease. The useful question to ask is which of these your specific findings support, and whether the aim is cure or control.

Patient Stories

Stories from our leukemia programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Have your subtype and regimen reviewed

Send the marrow reports, the flow cytometry panel, the chromosome and molecular results, the treatment already given and the latest blood counts. Our haematology team will return a written assessment within 48 hours of the file being complete, including whether the regimen proposed is the standard one for your type and risk group.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*